Evaluation of Access to Screening for Post-partum Depression Via the Postnatal Interview Within 8 Weeks of Birth in Women Who Have Gave Birth at the Troyes Hospital ( DEPRESSIONPP ) (DEPRESSIONPP)

Post-partum depression is defined as a depressive disorder with onset of symptoms in the year following childbirth. Several international studies have reported a prevalence of this condition of around pathology of around 15%. Santé publique France's 2021 national perinatal survey corroborated these figures, finding a prevalence of post-partum depression in France of in France of 16.7%. It is therefore a frequent pathology that can cause complications for both mother and child.

The complications both for the mother and for the mother-child bond. Indeed, post-partum depression can lead to an increased risk of infanticide, weaker mother-child attachment, and altered parental behaviour. post-partum depression can lead to maternal suicide (the second leading cause cause of maternal mortality in France). Despite the potential seriousness of severe depression and its impact on the on the mother-child bond, just under half of those suffering from severe depression suffering from severe depression consult a healthcare professional.

Fear of being judged or stigmatised, linked to misperceptions about the episode, is one of the main obstacles to consultation.

Of being judged or stigmatised, linked to erroneous representations of the depressive episode. Given the scale of this condition, and the difficulties young mothers face in seeking help for young mothers to seek help, it is vital to screen postpartum women as widely and post-partum women as early as possible. In view of the extent of this condition and the difficulties young mothers have in seeking help for young mothers, it is vital to screen post-partum women as widely and as post-partum. With this in mind, from July 2022, a compulsory early post-natal interview has been introduced, designed to screen for postpartum depression.

Study Overview

• Status: Recruiting
• Conditions: Depression, Postpartum
• Intervention / Treatment: Behavioral: depression post partum

Detailed Description

Main objective: To evaluate the associated factors, in particular referral by a professional as a determinant of whether or not the 'compulsory' early interview.

Secondary objective: To assess the economic, geographical and other factors associated and other factors associated with the compulsory early postnatal interview. Type of study: Observational, retrospective study. Population: Women who gave birth at the Centre Hospitalier de Troyes from July 2022 to October 2023. Assessment criteria : To be referred or not by a health professional during the early postnatal interview. Investigation plan: Send the information note and no objection to all eligible eligible women, together with the questionnaire and a T envelope to return the completed questionnaire. Inclusion criteria The study will include adult women who have given birth at the Centre hospitalier de Troyes between July 2022 and October 2023 and agreeing to take part in the study. Non-inclusion criteria The following will not be included in the study

• minors under the age of 18
• those protected by law (guardianship, curatorship and safeguard of justice)
• patients refusing to participate in the study

• Study Type: Observational
• Enrollment (Estimated): 400

Contacts and Locations

• Study Contact: Name: Stéphane Sanchez, DR; Phone Number: 0325497561; Email: recherche.clinique@hcs-sante.fr

Study Locations

• France
  • Grand-Est
    • Troyes, Grand-Est, France, 10000
      • Recruiting
      • Centre Hospitalier de Troyes
      • Contact: Stéphane Sanchez, MD; Phone Number: 0625036892

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Adult; Older Adult
• Accepts Healthy Volunteers: Yes

• Sampling Method: Non-Probability Sample

Study Population

the adult women who have given birth at the Centre Hospitalier de Troyes between July 2022 and October 2023.

Description

Inclusion criteria:

• The study will include adult women who have given birth at the Centre hospitalier de Troyes from July 2022 to October 2023
• and agreeing to take part in the study.

non inclusion criteria

• minors under the age of 18
• those protected by law (guardianship, curatorship and safeguard of justice)
• patients refusing to take part in the study

Study Plan

How is the study designed?

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Measure if the patient is yes or not to be referred by a healthcare professional during the early postnatal interview.	question	3 months

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Measure the socio-economic status	financial parameter	3 months
measure the declaration of a financial or non-financial obstacle	financial parameter	3 months
measure the knowledge about post-partum depression	question first contact	3 months
measure the knowledge about early post-natal interview.	question	3 months

Collaborators and Investigators

• Sponsor: Centre Hospitalier de Troyes
• Investigators: Principal Investigator: Amjad KATTINI, DR, Centre Hospitalier de Troyes

Study record dates

Study Major Dates

• Study Start (Actual): March 1, 2024
• Primary Completion (Actual): June 1, 2024
• Study Completion (Estimated): August 31, 2024

Study Registration Dates

• First Submitted: May 31, 2024
• First Submitted That Met QC Criteria: June 17, 2024
• First Posted (Actual): June 21, 2024

Study Record Updates

• Last Update Posted (Actual): June 21, 2024
• Last Update Submitted That Met QC Criteria: June 17, 2024
• Last Verified: June 1, 2024

More Information

Terms related to this study

• Keywords: depression post partum
• Additional Relevant MeSH Terms: Behavioral Symptoms; Mental Disorders; Mood Disorders; Pregnancy Complications; Puerperal Disorders; Female Urogenital Diseases and Pregnancy Complications; Urogenital Diseases; Depression; Depressive Disorder; Depression, Postpartum
• Other Study ID Numbers: 2023-A02394-41

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: UNDECIDED

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No